Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Col... ( SEATTLE June 19 /- Trubion Pharma...)

Trubion Pharmaceuticals Announces Extension of Research Period Under Its Wyeth Collaboration

Date:6/19/2008

SEATTLE, June 19 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period through Dec. 22, 2009. Under the terms of the research period extension, Wyeth's obligations to Trubion include collaboration research funding commitments of approximately $3.2 million in exchange for committed research services through Dec. 22, 2009.

"We are pleased that Wyeth has extended the research period of our collaboration," said Peter Thompson, M.D., FACP, president, CEO and chairman of Trubion. "Wyeth's ongoing commitment to the collaboration underscores the potential of our technology, and we look forward to continuing our efforts with Wyeth as we pursue the development of additional first-in-class and best-in-class compounds."

In December 2005, Trubion entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of TRU-015 and other CD20-directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to a small number of targets other than CD20 that have been established pursuant to the agreement. Unless earlier terminated, the agreement will remain in effect on a product-by-product basis and on a country-by-country basis until the later of the date that any such prod
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Trubion Pharmaceuticals Announces Presentation of Positive TRU-015 and SBI-087 Data at the 2008 Annual European Congress of Rheumatology Meeting
2. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
3. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
4. Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis
5. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
6. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
7. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
8. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
9. Peregrine Pharmaceuticals Awarded Two New U.S. Patents Broadening Its Targeted Anti-Phospholipid Patent Portfolio
10. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
11. Sunesis Pharmaceuticals Presents Data from Clinical Trials of Voreloxin (formerly SNS-595) in Patients with Acute Myeloid Leukemia at the 13th Congress of the European Hematology Association

Post Your Comments:

(Date:5/21/2013)... Wash. , May 21, 2013 IsoRay, Inc. ... today that it has entered into an exclusive international ... IsoRay,s complete product line in Greece ... in seed brachytherapy and medical radioisotope applications for brain ... and gynecologic ("gyn") cancer. IASIS Medical ...

(Date:5/21/2013)... Calif. , May 21, 2013 ... and manufacture of wireless personal healthcare products and ... its reach, announcing the release of two new ... blood pressure monitors and scales: the Wireless Pulse ... (Photo: http://photos.prnewswire.com/prnh/20130521/SF17618 ) ...

(Date:5/21/2013)... The North Shore-LIJ Health System is expanding a ... at North Shore University Hospital in Manhasset, ... at Forest Hills (NY) Hospital. ... new pilot program strengthens patient safety by providing hospitals ... first time in the US that remote video auditing ...

Breaking Medicine Technology:IsoRay Announces A New International Distributor For Greece 2 IsoRay Announces A New International Distributor For Greece 3 iHealth Lab adds new products and partners to mobile personal healthcare offering 2 iHealth Lab adds new products and partners to mobile personal healthcare offering 3 North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 2 North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 3 North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs 4

[0] IsoRay Announces A New International Distributor For Greece [0] iHealth Lab adds new products and partners to mobile personal healthcare offering [0] North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs

... Expand Testing Using Cellular ... Antioxidant Activity Assay, ... with the release of results from a new study,showing Wild ... red grapes and strawberries in an expanded,test using the Cellular ...

... Oct. 8 Vical Incorporated (Nasdaq: VICL ... nonclinical data,demonstrating that the company,s Vaxfectin(R) adjuvant may ... vaccines and,peptide-based cancer vaccines. Alain P. Rolland, Pharm.D., ... present the data today,Wednesday, October 8, at the ...

Cached Medicine Technology:Wild Blueberries Take Top Spot in New Antioxidant Research Study 2 Wild Blueberries Take Top Spot in New Antioxidant Research Study 3 Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2 Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3 Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4 Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5

Wild Blueberries Take Top Spot in New Antioxidant Research Study Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months

(Date:5/22/2013)... 2013 Athletic-Minded Traveler LLC, a ... released today its 2013 U.S. Business Hotel “Fit ... the company’s recommendation after ongoing research of over ... by the editorial staff. Selection criteria included ... court, etc.), in-room workout choices, healthy food offerings, ...

(Date:5/21/2013)... Swimsuit season is almost here. The "Get ... has begun with a 35% discount. , Cellulite forms mainly ... get the dreaded cellulite even if they are in shape. ... they have been stored as toxic lymph and smashed together, ... a specific program that works to dissolve the toxins and ...

(Date:5/21/2013)... 2013)Today the George Washington (GW) University School ... announced the launch of the Avance Center ... collaboration between SPHHS, the Maryland Multicultural Youth ... partners. This university-community partnership aims to address ... communities through research, mutual capacity building and ...

(Date:5/21/2013)... 2013 DISCcert has served the training ... use 17 DISC applications at the July 25 & ... , The July 25 & 26th DISC certification in ... of applying DISC. The time-tested, proven support materials will ... DISC training materials ; worksheets, handouts, learning ...

(Date:5/21/2013)... (PRWEB) May 21, 2013 ContinuCare Home ... Texas Department of Aging and Disability Services. After completing ... employee interviews, ContinuCare Home Health was found to ... review is part of the Department of Aging and ... aging and disability services, supports and opportunities that ...

Breaking Medicine News(10 mins):Health News:2013: The 10 Healthiest Business Hotels in the U.S. 2 Health News:Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale" 2 Health News:GW launches center to address health disparities in the Latino immigrant community 2 Health News:GW launches center to address health disparities in the Latino immigrant community 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3 Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4 Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2

[0] 2013: The 10 Healthiest Business Hotels in the U.S.[0] Diminish Cellulite for Swimsuit Season; Sublime Beauty Introduces Cellulite Whisperer® Products in the "Get Ready for Summer Sale"[0] GW launches center to address health disparities in the Latino immigrant community [0] DISCcert Offers 17 Applications in Coming DISC Certification [0] ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services

... (Nasdaq: CYNO ), a leading developer and ... systems, today announced financial results for the three and ... Results Consistent with Cynosure,s January 15, 2009 announcement, ... were $25.5 million, reflecting the effect of deteriorating global ...

... Feb. 10 Novasys Medical, Inc., a developer of ... one of the nation,s leading health insurers with over ... treatment for stress urinary incontinence (SUI) in non-pregnant women ... undergo surgery for their condition. According to Aetna,s updated ...

... Kit Offers Extensive Enrollment Information and Insights into ... Feb. 10 HealthLeaders-InterStudy , a leading ... District Survival Kit designed to provide pharmaceutical sales ... and analysis that drives innovative sales strategy development.Each ...

... quarter decline in procedure volume rate shows signs of ... 48% Provides near-term financial outlook CINCINNATI, Feb. 10 ... LCAV ), a leading provider of laser vision correction ... financial and operating results for the three and 12 ...

... OSF HealthCare and Seattle Children,s Hospital among the ... software suiteCLEVELAND, Feb. 10 Healthcare organizations ... healthy lifestyle. Now, hospitals and health systems are ... preaching. Paper medical records cause costly errors, potentially ...

... AHPI ) reported that its net income for ... or zero cents per share in the,prior year period, to ... per,share, primarily because of lower sales volume in the current ... the second quarter fell about 8 percent, or almost $1.1,million, ...

Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 Aetna Now Covers Novasys Medical's Renessa(R) Treatment for Incontinence in Women HealthLeaders-InterStudy Offers District Survival Kit to Arm Pharmaceutical Sales Teams With Local-Level Managed Care Market Intelligence LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results OnBase is the Choice for a Growing Number of Healthcare Organizations Allied Healthcare Reports Second Quarter Loss

... gas permeable contact lenses used for corneal ... nearsightedness (myopia). The patient wears the lenses ... wakening. During the day, nearsightedness is corrected ... Quadra RG contact lenses apply slight pressure ...

... all the major challenges to operating ... fair market fee for each procedure ... licensure requirements., Board Certified Nuclear Medicine ... camera., Hot Lab Equipment and Accessories., ...

... ,Type 330 ,Straight, ,Konan realized an ... illumination between lenses for observation. This ... in ophthalmology and otorhinolaryngology, ,Konan offers ... can; an advanced zoom function (1:3) ...

... and most experienced provider of mobile catheterization ... States. Mobile laboratories serving hospital networks are ... one hospital to another in a particular ... laboratory is fully equipped and operated by ...

Medicine Products:

Paragon Quadra RG (paflufocon B)Nuclear Cardiology Facility Planning Services Operation Microscope Mobile Catheterization Laboratories Serving Hospital Networks